What is the clinical evidence from this study?

Study design: Review. Population: Atherosclerosis and cancer.

What does this research mean for the field?

Atherosclerosis and cancer share interconnected molecular and cellular mechanisms—including chronic inflammation, clonal hematopoiesis, and metabolic dysregulation—that represent overlapping manifestations of common pathogenic processes. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the bidirectional molecular and cellular connections between atherosclerosis and cancer, establishing a unified pathogenic framework to guide cross-specialty diagnostic and therapeutic strategies.

September 19, 2026Cellular and Molecular BiologyOpen Access

Atherosclerosis and cancer share mechanisms like chronic inflammation and clonal hematopoiesis, offering shared therapeutic opportunities.

View Full Paper

Ask AI

Bookmark

Design

Review

Key result

Atherosclerosis and cancer share interconnected molecular and cellular mechanisms, including chronic inflammation, oxidative stress, and clonal hematopoiesis, offering shared therapeutic opportunities.

Authors

ABAlexander V. Blagov DBDaria D. Borodko URUlyana Rozhkova

Discussion

Member takes

Overview

May inform joint cardio-oncology risk prediction; leaves open whether targeting shared pathways improves outcomes.

Key Points

To evaluate the bidirectional molecular and cellular connections between atherosclerosis and cancer, establishing a unified pathogenic framework to guide cross-specialty diagnostic and therapeutic strategies.
Narrative synthesis of preclinical and clinical literature across cardiovascular biology, oncology, and immunology.
Evaluation of interconnected molecular drivers, including chronic inflammation, cellular senescence, macrophage polarization, clonal hematopoiesis of indeterminate potential (CHIP), and the gut microbiome.
Atherosclerosis and malignancy share core pathogenic drivers, particularly NLRP3 inflammasome activation, oxidative stress, metabolic reprogramming, and endothelial dysfunction.
Therapeutic interactions reveal bidirectional impacts, including cardiovascular drug effects on tumor biology and significant cardiovascular toxicities induced by common anticancer therapies.
Targeting shared molecular mediators provides actionable avenues for joint biomarker discovery, unified risk prediction, and coordinated cardio-oncology interventions.

PICO

Population

Atherosclerosis and cancer

Atherosclerosis and cancer share fundamental molecular mechanisms, particularly chronic inflammation and clonal hematopoiesis, highlighting the potential for shared biomarkers and mechanism-based therapeutic strategies in cardio-oncology.

Cite This Study

Blagov et al. (2026) conducted a review in Atherosclerosis and cancer. Atherosclerosis and cancer share interconnected molecular and cellular mechanisms, including chronic inflammation, oxidative stress, and clonal hematopoiesis, offering shared therapeutic opportunities.

synapsesocial.com/papers/6aae47640c69660b71ecc6b7 https://doi.org/10.14715/cmb/2026.72.5.6

View Full Paper

Ask AI

Bookmark

September 19, 2026Cellular and Molecular BiologyOpen Access

Atherosclerosis and cancer share mechanisms like chronic inflammation and clonal hematopoiesis, offering shared therapeutic opportunities.

View Full Paper

Ask AI

Bookmark

Design

Review

Key result

Authors

ABAlexander V. Blagov DBDaria D. Borodko URUlyana Rozhkova

Discussion

Member takes

Overview

May inform joint cardio-oncology risk prediction; leaves open whether targeting shared pathways improves outcomes.

Key Points

To evaluate the bidirectional molecular and cellular connections between atherosclerosis and cancer, establishing a unified pathogenic framework to guide cross-specialty diagnostic and therapeutic strategies.
Narrative synthesis of preclinical and clinical literature across cardiovascular biology, oncology, and immunology.
Evaluation of interconnected molecular drivers, including chronic inflammation, cellular senescence, macrophage polarization, clonal hematopoiesis of indeterminate potential (CHIP), and the gut microbiome.
Atherosclerosis and malignancy share core pathogenic drivers, particularly NLRP3 inflammasome activation, oxidative stress, metabolic reprogramming, and endothelial dysfunction.
Therapeutic interactions reveal bidirectional impacts, including cardiovascular drug effects on tumor biology and significant cardiovascular toxicities induced by common anticancer therapies.
Targeting shared molecular mediators provides actionable avenues for joint biomarker discovery, unified risk prediction, and coordinated cardio-oncology interventions.

PICO

Population

Atherosclerosis and cancer

Cite This Study

synapsesocial.com/papers/6aae47640c69660b71ecc6b7 https://doi.org/10.14715/cmb/2026.72.5.6

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark